Observational studyJournal for immunotherapy of cancer2025

PD-L1 phenotype classification based on expression in tumor and immune cells as a potential biomarker for optimizing anti-PD-1/CTLA-4 immunotherapies in NSCLC.

Jun Miyakoshi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.